Fig 2: Knockdown of SRSF9 inhibits the proliferation and migration of HCC cells. A Overall survival of patients with HCC with high and low expression of SRSF9 based on TCGA database; B–C Viability of shRNA-treated cells at each assay time point; D, E Positive staining of Ki67 in different treatment groups; F colony staining results for HCC cells treated with shRNA. G Staining results for migrated cells from different treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001 versus shNC group

Fig 3: High expression of SRSF9 in HCC tissues and cell lines. A mRNA level of SRSF9 in 374 HCC tissues and 50 paratumor tissues based on TCGA database; B mRNA level of SRSF9 in HCC and normal tissues from laboratory samples; C mRNA level of SRSF9 in normal liver cells (L02), a hepatoblastoma cell line (HepG2), and HCC cell lines (Huh-7 and Hep3B); D IHC results for SRSF9 in HCC and normal tissues from laboratory samples; E Correlation between SRSF9 expression and 1-year, 3-year, and 5-year survival rates of patients with HCC based on TCGA database. ***P < 0.001, ****P < 0.0001 versus the normal group (or L02 group). AUC > 0.7 indicated a high accuracy. AUC area under the curve

Fig 4: Correlation of SRSF9 expression with clinical features and prognosis of patients with HCC from TCGA database. A–C Relationship between SRSF9 expression and tumor stage, pathologic T, and histologic grade; D Univariate analysis of multiple factors in HCC; E Multivariate analysis of various factors contributing to HCC. P < 0.05 was considered significant. BMI body mass index

Fig 5: Methylation of SRSF9. A Methylation status of seven methylation sites of SRSF9; B Relationship between the methylation level of cg06116271 and the expression of SRSF9; C Overall survival for patients with high and low methylation status at cg06116271; D mRNA level of SRSF9 in cells treated with SAM; E mRNA level of SRSF9 in cells treated with DAC. *P < 0.05, **P < 0.01, ****P < 0.0001 versus control group. SAM: S-Adenosyl methionine; DAC: Decitabine